Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes.
Neurotensin (NT), a neuropeptide released in the gastrointestinal tract in response to several stimuli, is involved in the pathophysiology of colonic inflammation. However, the molecular mechanism(s) mediating this proinflammatory response remains unclear. We found that NCM460, non-transformed human colonocytes, express a functional high affinity NT receptor that mediates NT-induced Erk activation. By using NCM460 cells stably transfected with NTR1, we show that NTR1 activation leads to interleukin (IL)-8 secretion that is mediated via both NF-kappaB- and Erk-dependent pathways. In addition, NT-stimulated NF-kappaB activation is dependent on intracellular calcium release. NT-stimulated Erk activity requires Ras activation because overexpression of the dominant negative Ras mutant Ras-17N almost completely inhibits the Erk activation. Furthermore, NT directly stimulates Ras-GTP formation as shown by a Ras-GTP pull-down assay. By using reporter gene constructs containing targeted substitutions in the IL-8 promoter, we show that the NF-kappaB, AP-1, and to a lesser degree the C/EBP sites in the IL-8 promoter region are required for IL-8 gene expression induced by NT. In summary, our results demonstrate that NT stimulates calcium-dependent NF-kappaB and Ras-dependent Erk pathways that mediate the release of IL-8 from non-transformed human colonocytes. We speculate that these NT-related proinflammatory pathways are important in the pathophysiology of colonic inflammation.
Zhao
D
D
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Keates
A C
AC
Kuhnt-Moore
S
S
Moyer
M P
MP
Kelly
C P
CP
Pothoulakis
C
C
D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D002461:Cell Line, Transformed; D003001:Cloning, Molecular; D003110:Colonic Neoplasms / Q000378:metabolism*; D004247:DNA / Q000378:metabolism; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005799:Genes, Dominant / Q000235:genetics; D017930:Genes, Reporter; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007249:Inflammation; D016209:Interleukin-8 / Q000096:biosynthesis* / Q000378:metabolism; D007763:Lac Operon; D008024:Ligands; D008156:Luciferases / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009154:Mutation; D016328:NF-kappa B / Q000378:metabolism; D009496:Neurotensin / Q000378:metabolism*; D010766:Phosphorylation; D010957:Plasmids / Q000378:metabolism; D011401:Promoter Regions, Genetic; D012190:Retroviridae / Q000235:genetics; D015398:Signal Transduction; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured; D018631:ras Proteins / Q000378:metabolism
D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D007074:Immunoglobulin G; D016209:Interleukin-8; D008024:Ligands; D016328:NF-kappa B; D009496:Neurotensin; D004247:DNA; D008156:Luciferases; D020928:Mitogen-Activated Protein Kinases; D018631:ras Proteins; D002118:Calcium